methyl-3-(5-formyl-6-hydroxynaphthalen-2-yl)benzoate | 1093119-22-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: methyl-3-(5-formyl-6-hydroxynaphthalen-2-yl)benzoate
• 英文别名: Methyl 3-(5-formyl-6-hydroxy-2-naphthalenyl)benzoate；methyl 3-(5-formyl-6-hydroxynaphthalen-2-yl)benzoate
• CAS: 1093119-22-2
• 化学式: C₁₉H₁₄O₄
• 分子量: 306.318
• InChiKey: WXSWAZIIQXYJAM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.3
• 重原子数：
  23
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.05
• 拓扑面积：
  63.6
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  6-溴-2-羟基-1-萘醛 、 3-甲氧基羰基苯硼酸 在 四(三苯基膦)钯 、 sodium carbonate 作用下， 以 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 0.5h， 以19%的产率得到methyl-3-(5-formyl-6-hydroxynaphthalen-2-yl)benzoate
  参考文献：
  名称：

  [EN] INHIBITORS OF THE IRE-1/XBP-1 PATHWAY AND METHODS OF USING THEREOF
  [FR] INHIBITEURS DE LA VOIE IRE-1/XBP-1 ET PROCÉDÉS D'UTILISATION ASSOCIÉS

  摘要：

  本公开了具有以下公开的化学式的XBP-1/IRE-1抑制剂。还公开了制备和使用这些抑制剂治疗癌症，特别是B细胞癌症的方法。还公开了一种基因XBP-1敲除的癌症小鼠模型。此外，所公开的主题还涉及治疗患者的肿瘤和炎症性疾病的方法。例如，本文公开了一种方法，根据该方法，向需要治疗的患有肿瘤性疾病（例如B细胞慢性淋巴细胞白血病（CLL））的患者施用本文公开的化合物或组合物的有效量。XBP-1缺乏导致白血病细胞获得对其生存不利的表型，例如受损的BCR信号传导能力和S1P1的表面表达增加。

  公开号：

  WO2014176348A1

文献信息

• IRE-1alpha INHIBITORS
  申请人：MannKind Corporation

  公开号：US20140080832A1

  公开（公告）日：2014-03-20

  Compounds which directly inhibit IRE-1α activity in vitro, prodrugs, and pharmaceutically acceptable salts thereof. Such compounds and prodrugs are useful for treating diseases associated with the unfolded protein response and can be used as single agents or in combination therapies.

  直接抑制IRE-1α活性的化合物、前药及其药学上可接受的盐。这些化合物和前药可用于治疗与未折叠蛋白应答相关的疾病，并可作为单一药物或联合治疗的组分。
• INHIBITORS OF THE IRE-1/XBP-1 PATHWAY AND METHODS OF USING THEREOF
  申请人：H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC.

  公开号：US20160083361A1

  公开（公告）日：2016-03-24

  Disclosed are XBP-1/IRE-1 inhibitors having formula disclosed herein. Methods of making and using these inhibitors for the treatment of cancer, in particular B cell cancers, are also disclosed. Also disclosed is a genetic XBP-1-knockout cancer mouse model. In still further aspects, the disclosed subject matter relates to methods for treating oncological and inflammatory disorders in a patient. For example, disclosed herein are methods whereby an effective amount of a compound or composition disclosed herein is administered to a patient having an oncological disorder, for example B-cell chronic lymphocytic leukemia (CLL), and who is in need of treatment thereof. XBP-1 deficiency causes leukemic cells to acquire phenotypes that are disadvantageous for their survival, such as compromised BCR signaling capability and increased surface expression of S1 P1.

  本文披露了具有公式所述的XBP-1/IRE-1抑制剂。还披露了制备和使用这些抑制剂治疗癌症，特别是B细胞癌症的方法。此外，还披露了一种遗传XBP-1敲除癌症小鼠模型。在更进一步的方面，所披露的主题涉及用于治疗患者的肿瘤和炎症性疾病的方法。例如，本文披露了将公式所述的化合物或组合物的有效量给予患有肿瘤疾病（例如B细胞慢性淋巴细胞白血病（CLL））并需要治疗的患者的方法。XBP-1缺乏会导致白血病细胞获得对其生存不利的表型，例如受损的BCR信号传导能力和增加的S1 P1表面表达。
• IRE-1A INHIBITORS
  申请人：MannKind Corporation

  公开号：EP3150589A1

  公开（公告）日：2017-04-05

  The present invention relates to compounds which directly inhibit IRE-1α activity, and which are useful for treating diseases associated with the unfolded protein response and can be used as single agents or in combination therapies.

  本发明涉及直接抑制 IRE-1α 活性的化合物，这些化合物可用于治疗与未折叠蛋白反应相关的疾病，并可用作单药或联合疗法。
• Inhibitors of the IRE-1/XBP-1 pathway and methods of using thereof
  申请人：H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC.

  公开号：US10323013B2

  公开（公告）日：2019-06-18

  Disclosed are XBP-1/IRE-1 inhibitors having formula disclosed herein. Methods of making and using these inhibitors for the treatment of cancer, in particular B cell cancers, are also disclosed. Also disclosed is a genetic XBP-1-knockout cancer mouse model. In still further aspects, the disclosed subject matter relates to methods for treating oncological and inflammatory disorders in a patient. For example, disclosed herein are methods whereby an effective amount of a compound or composition disclosed herein is administered to a patient having an oncological disorder, for example B-cell chronic lymphocytic leukemia (CLL), and who is in need of treatment thereof. XBP-1 deficiency causes leukemic cells to acquire phenotypes that are disadvantageous for their survival, such as compromised BCR signaling capability and increased surface expression of S1P1.

  所公开的是具有本文所公开式的 XBP-1/IRE-1 抑制剂。还公开了制造和使用这些抑制剂治疗癌症，特别是 B 细胞癌症的方法。还公开了一种遗传 XBP-1 基因敲除癌症小鼠模型。在更多方面，所公开的主题涉及治疗患者肿瘤和炎症性疾病的方法。例如，本文公开的方法是将有效量的本文公开的化合物或组合物施用给患有肿瘤疾病（例如B细胞慢性淋巴细胞白血病（CLL））且需要治疗的患者。XBP-1 缺乏会导致白血病细胞获得不利于其存活的表型，如 BCR 信号转导能力受损和 S1P1 表面表达增加。
• IRE-1alpha Inhibitors
  申请人：MannKind Corporation

  公开号：US20160168116A1

  公开（公告）日：2016-06-16

  Compounds which directly inhibit IRE-1α activity in vitro, prodrugs, and pharmaceutically acceptable salts thereof. Such compounds and prodrugs are useful for treating diseases associated with the unfolded protein response and can be used as single agents or in combination therapies.